- Home
- CBRE vs KLTOW Comparison
CBRE vs KLTOW Comparison
Compare CBRE & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- KLTOW
- Stock Information
- Founded
- CBRE 1906
- KLTOW N/A
- Country
- CBRE United States
- KLTOW United States
- Employees
- CBRE N/A
- KLTOW N/A
- Industry
- CBRE Real Estate
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBRE Finance
- KLTOW Health Care
- Exchange
- CBRE Nasdaq
- KLTOW Nasdaq
- Market Cap
- CBRE 40.1B
- KLTOW N/A
- IPO Year
- CBRE 2004
- KLTOW 2022
- Fundamental
- Price
- CBRE $129.30
- KLTOW $0.03
- Analyst Decision
- CBRE Buy
- KLTOW
- Analyst Count
- CBRE 9
- KLTOW 0
- Target Price
- CBRE $133.33
- KLTOW N/A
- AVG Volume (30 Days)
- CBRE 2.1M
- KLTOW N/A
- Earning Date
- CBRE 02-13-2025
- KLTOW N/A
- Dividend Yield
- CBRE N/A
- KLTOW N/A
- EPS Growth
- CBRE 66.15
- KLTOW N/A
- EPS
- CBRE 3.10
- KLTOW N/A
- Revenue
- CBRE $34,313,000,000.00
- KLTOW N/A
- Revenue This Year
- CBRE $13.52
- KLTOW N/A
- Revenue Next Year
- CBRE $11.01
- KLTOW N/A
- P/E Ratio
- CBRE $41.62
- KLTOW N/A
- Revenue Growth
- CBRE 10.00
- KLTOW N/A
- 52 Week Low
- CBRE $82.75
- KLTOW N/A
- 52 Week High
- CBRE $142.00
- KLTOW N/A
- Technical
- Relative Strength Index (RSI)
- CBRE 41.60
- KLTOW N/A
- Support Level
- CBRE $125.38
- KLTOW N/A
- Resistance Level
- CBRE $140.70
- KLTOW N/A
- Average True Range (ATR)
- CBRE 3.43
- KLTOW 0.00
- MACD
- CBRE -1.51
- KLTOW 0.00
- Stochastic Oscillator
- CBRE 25.59
- KLTOW 0.00
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.